AFP and gastroesophageal junction adenocarcinoma: A phase II, multi-center, single-arm clinical study (NCT04609176) enrolled 36 patients with stage III-IV unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, whose AFP levels were more than twice the upper normal limit.